HENDERSON MICHAEL THOMAS 4

What Happened Michael Henderson, a director of Spyre Therapeutics, was granted a derivative award on 2026-05-27 giving him the right to purchase 8,026 shares of the company’s common stock. The Form 4 reports the acquisition as an award/grant (code A) with a reported transaction amount of $0.00 at grant — this reflects a grant of option-like rights rather than a cash purchase or sale.

Key Details

• Transaction date: May 27, 2026; Form 4 filed May 29, 2026 (timely filing).
• Transaction type: Award/Grant of a derivative right to acquire 8,026 shares (reported at $0.00 on grant).
• Vesting: The option right vests and becomes fully exercisable upon the earlier of May 27, 2027 or the Issuer’s 2027 annual meeting, subject to Henderson’s continuous service (see footnote).
• Shares owned after transaction: Not specified in this summary; see the Form 4 for reported post-transaction holdings.
• No immediate sale or exercise reported — this is a forward-looking award subject to vesting.

Context This filing documents a typical director equity award that vests over time; it does not represent an immediate purchase or sale and therefore is not an immediate market signal. The grant gives Henderson the right to buy shares in the future if vesting conditions are met. For investors tracking insider activity, outright purchases are often viewed as stronger signals than time-vesting awards, but director grants are common compensation practice.